Haleon plc

NYSE:HLN

Drug Manufacturers - Specialty & Generic

Healthcare
$9.08 +0.96%

+$0.08 today

Market cap
$39.85B
Beta
0.25
P/E (TTM)
29.2
EPS (TTM)
$0.11
Dividend yield
2.13%
52W Low $8.65High $11.28

Volume 19.46M

Average 8.79M

HLN EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Haleon plcNYSE: HLN

EBITDA · Q4 FY2025 · quarter ended Dec 2025

EBITDA grows 13.4% year over year

Q4 FY2025 EBITDA of £1.43B rose 13.4% year over year. Over 3 fiscal years it compounded at +9.7% a year.

Context

  • EBITDA amounted to 26.1% of revenue in FY2025, up 3.7 pp from a year earlier.
  • EBITDA increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 12 analysts of £3.3B (+14.7%) for the fiscal year ending Dec 2026, a pace similar to FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
£1.43B— QoQ
Last fiscal yearDec 2025
£2.88B+14.5% YoY
LTMJun 2025
£4.04B— YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.4%+112.6%+99.2 pp
1 year+14.5%+14.7%+0.2 pp
3-year CAGR+9.7%+8.4%-1.3 pp
5-year CAGR+7.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

GBP · from the income statement

Latest · FY2025
2.88B GBP
Year-over-year change
+14.5%
4-year CAGR
+6.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How HLN compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • EBITDA amounts to 24.4% of revenue for HLN, versus a peer median of 21.0%.
HLN Competitors
EBITDA for HLN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GSKGSK plcLTM Jun 2026£8.8B GBP+2.2%+6.5%26.5%
HLNHaleon plcLTM Jun 2025£4.04B GBP—+9.7%24.4%
CLColgate-Palmolive CompanyLTM Sep 2026$3.86B USD-19.7%+13.0%18.1%
KVUEKenvue Inc.LTM Sep 2026$3.26B USD+10.9%-3.6%21.0%
CHDChurch & Dwight Co., Inc.LTM Sep 2026$1.29B USD-5.3%+16.0%20.6%
PRGOPerrigo Company plcLTM Jun 2026-$1.05B USD-271.1%—25.2%
Peer median (excluding HLN) —-5.3%+9.8%21.0%

Competitors are the stored peer set for HLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

GBP
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue9.55B10.86B11.3B11.23B11.03B
Cost of Revenue3.6B4.28B4.34B4.29B3.83B
Gross Profit5.95B6.58B6.96B6.95B6.99B
Gross Margin62.3%60.6%61.6%61.9%63.3%
Research & Development257M300M311M298M308.1M
Selling, General & Admin3.79B4.04B4.29B4.33B4.36B
Operating Expenses4.31B4.75B4.97B4.74B4.43B
Depreciation & Amortization268M287M309M196M352.11M
EBITDA2.21B2.18B2.35B2.51B2.88B
EBITDA Margin23.2%20.1%20.8%22.4%26.1%
Operating Income1.64B1.83B2B2.21B2.41B
Operating Margin17.2%16.8%17.7%19.6%21.9%
Interest Income13M68.98M14M55M76.29M
Interest Expense16M347.36M414M394M332.55M
Other Income / Expenses(2M)(207M)(368M)(296M)(260M)
Income Before Tax1.64B1.62B1.63B1.91B2.15B
Pre-Tax Margin17.1%14.9%14.4%17.0%19.5%
Income Tax Expense197M499M517M435M461.66M
Net Income1.39B1.06B1.05B1.44B1.63B
Net Margin14.6%9.8%9.3%12.8%14.8%
EPS (Basic)0.300.240.240.320.36
EPS (Diluted)0.300.240.240.320.36
Weighted Avg Shares4.62B4.62B4.63B4.57B4.48B
Weighted Avg Shares (Diluted)4.62B4.62B4.63B4.59B4.51B

Haleon plc

NYSE:HLN

Intrinsic Alpha fair value

Locked

Current Price

$9.08

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.